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ABSTRACT
Objectives: Current models of clonal expansion in human
Barrett’s oesophagus are based upon heterogenous, flow-
purified biopsy analysis taken at multiple segment levels.
Detection of identical mutation fingerprints from these
biopsy samples led to the proposal that a mutated clone
with a selective advantage can clonally expand to fill an
entire Barrett’s segment at the expense of competing
clones (selective sweep to fixation model). We aimed to
assess clonality at a much higher resolution by
microdissecting and genetically analysing individual
crypts. The histogenesis of Barrett’s metaplasia and neo-
squamous islands has never been demonstrated. We
investigated the oesophageal gland squamous ducts as
the source of both epithelial sub-types.
Methods: Individual crypts across Barrett’s biopsy and
oesophagectomy blocks were dissected. Determination of
tumour suppressor gene loss of heterozygosity patterns,
p16 and p53 point mutations were carried out on a crypt-
by-crypt basis. Cases of contiguous neo-squamous islands
and columnar metaplasia with oesophageal squamous
ducts were identified. Tissues were isolated by laser
capture microdissection and genetically analysed.
Results: Individual crypt dissection revealed mutation
patterns that were masked in whole biopsy analysis.
Dissection across oesophagectomy specimens demon-
strated marked clonal heterogeneity, with multiple
independent clones present. We identified a p16 point
mutation arising in the squamous epithelium of the
oesophageal gland duct, which was also present in a
contiguous metaplastic crypt, whereas neo-squamous
islands arising from squamous ducts were wild-type with
respect to surrounding Barrett’s dysplasia.
Conclusions: By studying clonality at the crypt level we
demonstrate that Barrett’s heterogeneity arises from
multiple independent clones, in contrast to the selective
sweep to fixation model of clonal expansion previously
described. We suggest that the squamous gland ducts
situated throughout the oesophagus are the source of a
progenitor cell that may be susceptible to gene mutation
resulting in conversion to Barrett’s metaplastic epithelium.
Additionally, these data suggest that wild-type ducts may
be the source of neo-squamous islands.
Barrett’s oesophagus is the replacement of the
normal oesophageal stratified squamous epithe-
lium with metaplastic glandular epithelium in
response to inflammation and ulceration provoked
by duodeno-gastroesophageal reflux.1 Oesophageal
adenocarcinoma can arise from progression through
a metaplasia–dysplasia–carcinoma sequence (MCS),
and the presence of Barrett’s oesophagus increases
the risk of oesophageal adenocarcinoma by 30- to
40-fold.2
Serial biopsies and molecular analysis of a cohort
of patients with Barrett’s oesophagus has enabled
researchers to study the evolution of common
tumour suppressor gene mutation patterns as the
MCS progresses. These longitudinal clonal ordering
studies have shown that genetic and epigenetic
inactivation of cyclin-dependent kinase N2 (p16) and
genetic inactivation of TP53 (p53) tumour suppres-
sor genes occur early in the MCS3 with 88% of pre-
dysplastic Barrett’s oesophagus tissue having a
detectable p16 lesion.4 The demonstration of clonal
p16 and p53 lesions throughout long lengths of
Barrett’s oesophagus4 5 suggests a common precursor
lesion that undergoes clonal expansion, and has led
to the proposal that the MCS progresses as a
consequence of sequential tumour suppressor gene
inactivation causing selective growth advantages.
Growth advantages result in preferential expansion
of a mutated clone and a mutation is said to have
‘‘gone to fixation’’ when it expands throughout an
entire field, extinguishing all competing clones. A
‘‘selective sweep’’ is the process of natural selection
driving a mutation to fixation.6 7 It has been
suggested that loss of each of the two p16 alleles
predisposes to a selective sweep, and that p16
mutation fixation occurs early in the progression of
Barrett’s oesophagus.6 The demonstration of similar
p16 loss of heterozygosity (LOH), methylation and
point mutation patterns in biopsy material taken
from different levels of long Barrett’s oesophagus
segments supports widespread clonal expansion and
fixed mutations.4 However, phenotypic and geno-
typic heterogeneity has also been described in some
Barrett’s segments4 5 and clonal diversity in Barrett’s
segments has recently been shown to be associated
with progression to adenocarcinoma.8
Despite years of active research the histogenesis of
Barrett’s oesophagus has never been demonstrated.
Different theories have been proposed: proximal
migration of the gastric cardia; re-differentiation of
the squamous epithelium and colonisation of cells
from the oesophageal gland ducts.9 10 Similar ques-
tions remain regarding the origin of neo-squamous
islands that can arise within fields of Barrett’s tissue
after acid suppression or endoscopic ablative ther-
apy.11 12 Paulson et al13 demonstrated that these
squamous islands were usually genetically wild-type
despite being surrounded by mutated Barrett’s tissue.
They excluded encroachment of adjacent normal
squamous epithelium by only including patients
who developed isolated squamous islands, but were
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unable to determine the source of the genetically normal tissue
that may have an important clinical role in re-epithelisation after
treatment for Barrett’s oesophagus.
To date, most clonality studies have been carried out on
heterogenous flow-purified whole biopsy samples. In this work
our aims were to (1) study clonality at a crypt-by-crypt level,
avoiding problems associated with contaminating normal
stroma; and (2) examine the oesophageal gland squamous ducts
as the potential source of Barrett’s columnar epithelium and
neo-squamous islands.
MATERIALS AND METHODS
Tissue and slides
Paraffin-embedded biopsy (six biopsies from five patients) and
oesophagectomy blocks (four blocks from patient 1, four blocks
Figure 1 Laser capture microdissection. A(i) Individual crypts were identified using haematoxylin & eosin (H&E) slides A(ii) Cytokeratin 7
immunostaining of serial sections showing glandular differentiation of columnar lined oesophagus. A(iii), (iv) Individual crypts were microdissected from
serial sections stained with methylene green and mounted on laser capture slides. B(i) Squamous islands were identified histologically using H&E
slides. B(ii) Cytokeratin 13 immunostaining of serial sections showing mature squamous cell differentiation. B(iii) Squamous island after laser capture
showing selective dissection of only squamous tissue. C(i), (ii) Individual structures were dissected evenly from across the block and numbered.
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from patient 2 and two blocks from patient 3) were obtained
from the pathology archives of Leicester General Hospital.
Tissue was independently assessed for Barrett’s metaplasia and
dysplasia according to British Society of Gastroenterology 2005
guidelines (www.bsg.org.uk), by at least two pathologists.
Serial 5 mm sections were cut. Sections 1–3 and 5–7 were
mounted onto P.A.L.M. membrane slides (P.A.L.M. Microlaser
Technologies, Benried, Germany) and were stained with
methylene green. Section 4 was stained with haematoxylin &
eosin (H&E).
Laser capture microdissection (fig 1)
Suitable crypts for dissection were identified using the H&E
slide. The same crypts were identified on the slides stained with
methylene green. Individual crypt sections from the six serial
slides were cut out from the laser capture slides and catapulted
into the adhesive caps of eppendorfs using the P.A.L.M. Laser
Microdissection system. Where constitutional DNA was
required for microsatellite analysis, serial areas of lamina propria
were microdissected. Catapulted sections on the cap were
immersed in 12 ml of proteinase K solution (Arcturus Bioscience,
Mt View, California, USA). After individual crypt dissection
residual epithelial tissue was catapulted into a single tube and
immersed in 30 ml proteinase K for p53 gene screening. Negative
control tubes containing 12 ml proteinase K solution and no
laser capture material were included. Tubes were then
centrifuged at 4.5 g for 1 min and incubated at 65uC overnight.
A 10 min incubation at 95uC denatured the proteinase K and the
lysate was then stored at 220uC.
Immunocytochemistry
Cytokeratin 7 and 13 staining was used to demonstrate
glandular and squamous epithelial differentiation respec-
tively.14 15 Serial sections of oesophagectomy blocks were cut
at 4 mm and mounted on glass slides. Sections were de-waxed
and rehydrated by standard methods. Endogenous peroxidase
was blocked with 3% H2O2 in methanol for 10 min. Antigen
retrieval was achieved by 10 min microwaving in sodium citrate
buffer at pH 6. Slides were incubated in 3% bovine serum
albumin in phosphate-buffered saline (PBS) for 15 min. Slides
underwent primary antibody incubation with mouse mono-
clonal antibodies against cytokeratin 7 (1:100 dilution of clone
OV-TL; Abcam, Cambridge, UK) or cytokeratin 13 (1:200
dilution of clone AE8; Abcam). This was followed by
biotinylated rabbit anti-mouse secondary antibodies before
application of a 1:500 dilution of the tertiary layer of
peroxidase-conjugated streptavidin (strep-HRP; Dako,
Glostrup, Denmark). Each layer was applied for 45 min and
three 5 min PBS washes were performed between layers.
Sections were then developed with 3,3-diaminobenzidine
tetrahydrochloride solution (DAB; Sigma, Poole, UK) for
2 min, followed by rinsing in tap water and light haematoxylin
counterstaining. The positive control tissues used were duode-
num (CK 7) and tonsil (CK 13). Negative controls underwent all
steps but were incubated with PBS instead of the primary
antibody solution.
Nested polymerase chain reaction and sequencing
First and second round primers were designed to amplify exons
5–9 of p53 and exon 2 of p16, using the primer 3 website (MIT,
Cambridge, Massachusetts, USA). First round oligonucleotide
primer pairs were specifically designed to amplify a region that
included the amplicon covered by the primers used in the second
round of the polymerase chain reaction (PCR). Primer optimisa-
tion determined the optimum reagent concentration and
annealing temperature for each primer pair. Primer sequences
are tabulated in the supplementary information (supplementary
table 1A–C). Both PCR steps were carried out in an Omni PCR
UV hood to minimise contamination (Bioquell, Andover,
Berkshire, UK). Only products with an uncontaminated
negative control tube went forward for sequencing. PCR
product was sequenced using BigDye terminator cycle sequen-
cing on an ABI 3100 DNA sequencer (Applied Biosystems,
Foster City, California, USA). The sequences obtained were
directly compared to the revised Cambridge reference sequence,
and any identified mutations were checked against the
Catalogue of Somatic Mutations in Cancer (COSMIC) database
(www.sanger.ac.uk) (Cambridge, UK). Sequencing was
repeated twice from dissection lysate for the oesophageal gland
squamous duct work.
Microsatellite analysis
Three microsatellite markers; D5S346 (APC gene), D9S932 (p16
gene) and D17S786 (p53 gene), were used for LOH analysis.
Constitutionally homozygous markers were scored as non-
informative. Forward oligonucleotide primers were labelled at
the 59 end with the carboxy fluorescein (FAM) fluorescent marker
(Sigma). PCR amplifications were performed using the LA
TAKARA kit (Takara Bio, Shiga, Japan). The PCR product was
analysed on an ABI 3100 sequencer (Applied Biosystems) and
genotyper 2.5 software (Perkin-Elmer, Boston, Massachusetts,
USA). At each marker, loss of heterozygosity was considered
present if the area under one allelic peak in the affected crypt was
less than 0.5 times or greater than 2 times that of the other allele,
after correcting for the relative areas using constitutional DNA
(microdissected areas of lamina propria tissue).
Statistical analysis
The associations between individual crypt point mutations and
tumour suppressor gene allelic loss were analysed using the two-
tailed Fisher’s exact test run on Prism 4.0 software (Graphpad
Software, San Diego, California, USA).
RESULTS
Biopsies
Thirty-seven individual crypts and seven squamous islands were
dissected from six biopsies taken from five patients. Analysis of
individual crypts from biopsy samples allowed detection of
LOH patterns in p16, p53 and adenomatous polyposis coli (APC)
tumour suppressor genes which is not demonstrable when the
whole biopsy section was digested and analysed. This is likely to
be a consequence of a diluting effect of the normal stroma in the
whole biopsy sample (fig 2 and supplementary fig 1)
Oesophagectomy blocks
One hundred and twenty-seven individual Barrett’s crypts and
14 squamous islands were dissected from 10 oesophagectomy
blocks from three patients. Squamous islands were defined as an
area of squamous mucosa seen completely surrounded and
engulfed by metaplastic tissue. Suprabasal squamous island
immunostaining with cytokeratin 13 antibody demonstrated
squamous differentiation. Clonal heterogeneity of LOH pat-
terns and identified point mutations were found in all of the
oesophagectomy blocks. The identification of distinct point
mutations is a powerful tool for the demonstration of clonality,
and one patient had two different p16 point mutations in crypts
Oesophagus
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from different blocks indicating the presence of at least two
separate clones (fig 3). No single fixed mutation was identified
throughout every dissected crypt from an entire block, although
some p53 point mutations were present in multiple blocks from
the same patient (supplementary fig 2). Individual Fisher’s exact
tests were calculated for each point mutation and allelic loss.
The calculated p-values are tabulated and show a significant
association between p53 point mutations and loss of any of the
three alleles. No association was seen between p16 point
mutation and tumour suppressor gene LOH.
Oesophageal gland squamous ducts
All but one of the dissected squamous islands were wild-type,
despite often being surrounded by fields of mutated Barrett’s
crypts. Wild-type squamous islands were seen overgrowing
mutated deep Barrett’s oesophagus crypts as a thin surface layer
and this is consistent with previous results, particularly after
attempts at ablative treatment of Barrett’s.11 Moreover, it was
common to find squamous islands situated overlying deeper
oesophageal glands. In one case a squamous island was seen
arising from an oesophageal gland duct encroaching onto a field
of Barrett’s oesophagus (fig 4A). Microdissection of the
surrounding Barrett’s epithelium revealed a p53 non-sense point
mutation; however, the underlying squamous island and
contiguous oesophageal gland squamous duct were p53 wild-
type, indicating the presence of a different clone to the
surrounding Barrett’s dysplasia. In three tissue blocks it was
also possible to identify oesophageal squamous duct epithelium
in continuity with metaplastic Barrett’s crypts similar to the
findings of Coad et al.16 In one case careful microdissection of
the metaplastic epithelium revealed a silent point mutation in
exon 2 of p16, which was also seen in the separately dissected
squamous duct (fig 4B). The mutation is non-coding and is
therefore unlikely to be the founder mutation responsible for
metaplastic transition but does serve as a useful clonal marker
showing a clonal origin of both epithelial types and suggesting
that metaplastic epithelium arises from squamous duct origin.
The same mutation was also detected in the oesophageal gland
acini suggesting bi-directional flow of mutated cell progeny
similar to that seen in the Brunner’s gland.17
DISCUSSION
This study has improved upon previous clonality studies in
Barrett’s oesophagus by studying the clonal origin of individual
crypts rather than purified whole biopsy specimens. We have
shown here that single biopsies can be phenotypically and
genotypically heterogeneous, and analysis of whole biopsy
samples masked some of the mutations picked up on individual
crypt analysis. Thus, genetic analysis of whole biopsy samples,
even those that are well targeted, may not detect all mutations
or clones, throwing into doubt their use as surveillance
biomarkers in Barrett’s oesophagus since minority clones in
the sample may not be detected.
Figure 2 Oesophageal biopsy clonal
map. Individual crypts, squamous islands
and areas of lamina propria were
microdissected from oesophageal
biopsies and analysed for tumour
suppressor gene loss of heterozygosity
(LOH). An unstained serial section of the
whole biopsy was then scraped into
proteinase K using a clean scalpel blade,
and the lysate analysed. LOH of individual
alleles is denoted by a blue- or red-
coloured box. The table is the clonal map
obtained from a single biopsy and each
column within the table represents
genetic analysis of a single crypt or area
of lamina propria. In each case the
shortest allele is referred to as A1 and the
longest A2. Non-informative markers are
denoted by a black box. Individual crypts
often demonstrated LOH not detectable
on the whole biopsy section lysate
probably as a consequence of a diluting
effect of wild-type stroma in the whole
biopsy lysate. Other biopsy clonal maps
are presented in the supplementary
information (supplementary fig 1).
H&E, haematoxylin & eosin.
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Dissection across large oesophagectomy blocks also revealed
considerable phenotypic and genotypic heterogeneity in all
cases. p16 point mutations were limited to single blocks and
were not significantly associated with loss of any alleles;
however, there was a significant association (Fisher’s exact test
p,0.004) between p53 point mutations and allelic loss of all
three tumour suppressor genes. This is consistent with
functional loss of the cell cycle checkpoint activity of TP53
protein, which is then permissive for widespread, large-scale
genetic changes. Additionally, p53 point mutations, although
not seen in every crypt, were often present in multiple blocks
from a single oesophagectomy specimen, suggesting widespread
Figure 3 Clonal maps of two blocks from patient 1. Each table is the clonal map for the oesophagectomy specimen pictured and each column within
the table represents the genetic analysis of a single crypt, squamous island or area of lamina propria. p16 point mutations are denoted by green- or
yellow-coloured boxes as per the key. White boxes are wild-type. Clonal analysis revealed regional similarities in loss of heterozygosity (LOH) patterns
correlating with the observed phenotypic differences; however, there was no evidence of tissue-wide selective sweeps and no fixed founder mutations
indicating a common ancestral precursor. Two different, independent p16 point mutations were identified in the different blocks suggesting at least two
distinct clones. Only one squamous island contained a mutation and this is comparable with the results described by Paulson et al13 Clonal maps from
other patients are presented in the supplementary information (supplementary fig 2).
Oesophagus
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and far-reaching clonal expansion as a consequence of the
strong selective advantage that p53 loss would provide
(supplementary fig 2). This is similar to the findings by Prevo
et al,18 but our individual crypt analysis technique also allows
detection of competing p53 wild-type clones, which may have
been masked in whole biopsy samples.
Phenotypic and genotypic heterogeneity in Barrett’s tissue has
been well described,4 5 8 including patients with multiple distinct
p53 point mutations.18 This heterogeneity has previously been
explained by clone bifurcation with genetic divergence of an
original single population; however, such bifurcation importantly
assumes the presence of an original founder, fixed mutation
which should still be able to identify all crypts, despite subsequent
genetic divergence. Using our crypt-by-crypt analysis we have
failed to show a single founder mutation present in every crypt
throughout an entire block, including p16 inactivation. Bi-allelic
loss of p16 in some crypts means that epigenetic methylation is
unlikely to be an undetected founder mutation. p16 inactivation
by allelic loss, point mutation or methylation is one of the
proposed earliest lesions in the Barrett’s MCS pathway and is said
to predispose towards a selective sweep.6 We could find no
evidence of fully fixed mutations: on the other hand regional LOH
and point mutation patterns could be identified. This suggests
sweeps of clonal expansion may be localised amongst multiple
independent clones, rather than a single founder mutation
sweeping through an entire Barrett’s segment to fixation.
Figure 4 (A) Oesophageal gland squamous ducts give rise to neo-squamous islands. The haematoxylin & eosin (H&E) slides show a squamous island
originating from an oesophageal gland squamous duct and encroaching onto a field of Barrett’s dysplasia. Dissection of the continuous dysplastic tissue
revealed a p53 non-sense mutation, which was not present in the separately dissected squamous tissue and squamous duct. It has been previously
noted that squamous islands are often associated with oesophageal glands,16 and this demonstrates the oesophageal gland duct as the source of these
wild-type islands. (B) Oesophageal gland squamous ducts give rise to metaplastic columnar epithelium. The H&E slides show a metaplastic glandular
crypt arising from a contiguous squamous duct with a clear transition from squamous to columnar epithelium (black arrow). The same mutation was
found in both the squamous and columnar epithelial tissue suggesting a clonal origin.
Table 1 Fisher’s exact tests showing association between each point
mutation and individual allelic loss
Mutation p53 LOH p16 LOH APC LOH
p53 point mutation p = 0.0034 p = 0.0003 p,0.0001
p16 point mutation p = 0.42 p = 0.21 p = 0.08
LOH, loss of heterozygosity.
Oesophagus
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It has been proposed, but never proven, that submucosal
oesophageal gland ducts may be the origin of metaplastic tissue
in Barrett’s oesophagus.10 16 19 These results support this
hypothesis by demonstrating a p16 point mutation originating
in microdissected squamous duct tissue that was also found in
the adjoining metaplastic crypt. The presence of an identical
mutation in the two different epithelial types is strong evidence
to suggest that the origin of the metaplastic tissue in human
Barrett’s oesophagus is a progenitor located in the oesophageal
gland squamous ducts. Additionally, the presence of a wild-type
squamous island seen emerging from a wild-type squamous
duct in the midst of, and completely surrounded by, a p53
mutant field, strongly indicates a new clone development. This
supports the hypothesis that neo-squamous islands can arise de
novo from glandular tissue after Barrett’s ablation therapy,20 and
extends the findings by Paulson et al13 by showing that these wild-
type islands arise from non-mutated squamous duct tissue.
The demonstration of multiple competing independent clones
and the identification of the origin of Barrett’s oesophagus from
the oesophageal gland squamous duct, structures present through-
out the length of the oesophagus, allows the development of a new
model of clonal evolution in Barrett’s oesophagus. We suggest that
duodeno-gastro-oesophageal reflux-induced ulceration and inflam-
mation can induce tumour suppressor gene mutations in some of
the stem cell populations located in oesophageal gland squamous
ducts. This gives rise to multiple distinct clones of metaplastic
tissue that then compete to colonise the oesophagus, creating a
mosaic pattern of clones across the segment. Clonal expansion of
populations with greater selective advantage leads to dominant
and widespread clones; however, no single mutation is fixed since
competing wild-type clones are also identifiable. Non-mutated
squamous ducts are likely to be the source of wild-type squamous
islands (fig 5). These data are unable to rule out extension of
mutated tissue from the oesophageal–gastric junction; however,
we propose that the oesophageal gland ducts should be considered
as an alternative or additional source of the multiple independent
clones we have demonstrated here.
The cell biology of the oesophageal epithelium has been
inadequately studied despite the high mortality and increasing
incidence of cancer at this site. The interpapillary basal layer has
been suggested as a possible stem cell zone21 but the
demonstration of Barrett’s metaplasia arising from oesophageal
squamous ducts raises an interesting analogy with the skin,
another stratified squamous epithelium. In the epidermis, stem
cells not only reside in the interfollicular epithelium but also in
associated deeper structures; specifically, the bulge region of the
hair follicle.21 The clinical significance of a possible oesophageal
gland duct stem cell niche, both as the source of Barrett’s
metaplasia and wild-type squamous islands, means that these
structures warrant further detailed analysis.
Figure 5 Clonal evolution models in
Barrett’s oesophagus. (A) The current
model of clonal evolution adapted from
Maley et al.6 A founder mutation (red
cross) occurs in a single progenitor and
provides a growth advantage that
predisposes to a selective sweep.
Successive selective sweeps result in
progression along the metaplasia–
dysplasia pathway. Clone bifurcation is
responsible for clonal heterogeneity in
this model. (B) Newly proposed model of
evolution based on the mutation of
multiple progenitor cells situated in the
oesophageal gland squamous ducts
located throughout the length of the
oesophagus (red crosses). Multiple
independent clones then arise which
evolve separately. The presence of
multiple different clones gives rise to a
mosaic interdigitating clonal pattern of
the Barrett’s segment represented here
by the striped areas.
Oesophagus
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In conclusion, we have demonstrated two important features
of Barrett’s oesophagus. First, clonal heterogeneity arises from
multiple independent clones, previously undetectable by whole
biopsy analysis; and second, Barrett’s metaplasia and neo-
squamous islands can arise from the oesophageal gland
squamous ducts.
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Robin Spiller, editor
A rare cause of ‘‘cellulitis’’
CLINICAL PRESENTATION
A 74-year-old man presented to the emergency department with
lower back pain and left lower quadrant pain. His medical
history included Parkinson’s disease and left inguinal hernia
repair. He was dyspnoeic and coughing.
On examination, he had fever (39.6uC), increased breath
sounds and pain in left lower quadrant without rebound
tenderness. Clinical examination revealed no other abnormal-
ities, most especially the left thigh. Laboratory data showed
leucocytosis (16.66109/litre) and an elevated C reactive
protein (301 mg/l). Chest x ray demonstrated pneumonia.
Intravenous antibiotic treatment (amoxicillin/clavulanate,
1200 mg every 8h) was initiated. During the next few days his
fever remained (38.3uC). His left leg became red, oedematous and
painful. No signs of abscess formation were present. The swelling
and erythema were progressive. Blood cultures grew enteric
bacteria and the lower quadrant pain persisted. An abdominal
computed tomography (CT) scan was performed followed by CT
scans of thorax and extremities (fig 1).
QUESTION
What is the diagnosis?
See page 1089 for the answer
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Figure 1 Reconstructed coronal image of
the computed tomography scan.
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